Eli Lilly’s diabetes, weight loss pill trial - Search News

News

Zepbound beats Wegovy for weight loss

Seeking Alpha on MSN · 3d

Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( NVO) Wegovy (semaglutide) in a Phase 3b head-to-head trial.

Indianapolis Business Journal · 1d

Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last month.

Big News Network · 17h

Zepbound beats Wegovy for weight loss in trial of blockbuster drugs

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct comparison of the two blockbuster medications

Zepbound vs. Wegovy: Here's which weight loss drug worked best in first trial

A trial was conducted comparing weight loss medications Zepbound and Wegovy ... one other weight-related health ...

Breakthrough weight-loss pill expected to launch within 12 months

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

FDA Accepts Novo Nordisk’s Application for Oral Wegovy: 5 Things to Know

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Applied Clinical Trials Online3d

Tirzepatide Demonstrates Superior Weight Loss to Semaglutide in 72-Week Phase IIIb SURMOUNT-5 Trial

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

Asian News International on MSN3d

Weight loss drug Mounjaro shown more effective than Wegovy, claims Pharma company

Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results